Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Viatris stock in Canada

Own Viatris shares in just a few minutes.

Viatris Inc is a drug manufacturers-specialty & generic business based in the US. Viatris shares (MYL) are listed on the NASDAQ and all prices are listed in US Dollars. Viatris employs 35,000 staff and has a trailing 12-month revenue of around USD$11.5 billion.

How to buy shares in Viatris

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MYL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Viatris stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Viatris stock price

Use our graph to track the performance of MYL stocks over time.

Viatris shares at a glance

Information last updated 2021-01-17.
52-week range$0.08 - $16.10
50-day moving average $16.42
200-day moving average $16.12
Wall St. target price$21.75
PE ratio 30.7267
Dividend yield N/A (0%)
Earnings per share (TTM) $0.52

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
FREE TRADES
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Get 2 free stocks when you open a Wealthsimple Trade personal account and deposit and trade at least $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
BMO InvestorLine
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$9.95
$9.95 + $1.25 per options contract
$0 if conditions met, otherwise $25/quarter
$0 - $9.95
Buy and sell a select group of Canada’s most popular ETFs without paying commissions.
An easy-to-use online trading platform with access to research, tools, and the option to access InvestorLine adviceDirect for additional professional support.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$4.99-$9.99
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$0
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$6.95
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
OFFER
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
OFFER
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Get up to 50 free trades. Be one of the first 100 new Qtrade clients to use the promo code 50FREETRADES and deposit a minimum of $10,000 (or top up to $15,000 to get $150 transfer fees waived). Valid until December 31, 2021.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

Is Viatris under- or over-valued?

Valuing Viatris stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Viatris's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Viatris's P/E ratio

Viatris's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, Viatris shares trade at around 31x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Viatris's PEG ratio

Viatris's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.59. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Viatris's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Viatris's EBITDA

Viatris's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.5 billion.

The EBITDA is a measure of a Viatris's overall financial performance and is widely used to measure a its profitability.

Viatris financials

Revenue TTM $11.5 billion
Operating margin TTM 15.72%
Gross profit TTM $4.6 billion
Return on assets TTM 3.63%
Return on equity TTM 0%
Profit margin 2.31%
Book value $24.27
Market capitalisation $8.6 billion

TTM: trailing 12 months

Shorting Viatris shares

There are currently 47.1 million Viatris shares held short by investors – that's known as Viatris's "short interest". This figure is 1.4% up from 46.5 million last month.

There are a few different ways that this level of interest in shorting Viatris shares can be evaluated.

Viatris's "short interest ratio" (SIR)

Viatris's "short interest ratio" (SIR) is the quantity of Viatris shares currently shorted divided by the average quantity of Viatris shares traded daily (recently around 4.2 million). Viatris's SIR currently stands at 11.15. In other words for every 100,000 Viatris shares traded daily on the market, roughly 11150 shares are currently held short.

However Viatris's short interest can also be evaluated against the total number of Viatris shares, or, against the total number of tradable Viatris shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Viatris's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Viatris shares in existence, roughly 90 shares are currently held short) or 0.1105% of the tradable shares (for every 100,000 tradable Viatris shares, roughly 111 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Viatris.

Viatris's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Viatris.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Viatris's total ESG risk score

Total ESG risk: 37.23

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Viatris's overall score of 37.23 (as at 01/01/2019) is pretty weak – landing it in it in the 78th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Viatris is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Viatris's environmental score

Environmental score: 1.95/100

Viatris's environmental score of 1.95 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Viatris is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Viatris's social score

Social score: 20.21/100

Viatris's social score of 20.21 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Viatris is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Viatris's governance score

Governance score: 14.07/100

Viatris's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Viatris is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Viatris's controversy score

Controversy score: 4/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Viatris scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Viatris has a damaged public profile.

Viatris share dividends

We're not expecting Viatris to pay a dividend over the next 12 months.

Have Viatris's shares ever split?

Viatris's shares were split on a 3:2 basis on 9 October 2003. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Viatris shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Viatris shares which in turn could have impacted Viatris's share price.

Viatris share price volatility

Over the last 12 months, Viatris's shares have ranged in value from as little as $0.077 up to $16.1. A popular way to gauge a stock's volatility is its "beta".

MYL.US volatility(beta: 1.47)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Viatris's is 1.4656. This would suggest that Viatris's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Viatris overview

Mylan N. V. , together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health.

Frequently asked questions

Viatris in the news

There are no recent company news
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site